MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

daca sunteti alergic (hipersensibil) la oricare dintre celelalte componente ale acestui medicament (enumerate la pct. 6); Known hypersensitivity to meloxicam or any excipients of the product. There is a potential for cross sensitivity to aspirin and other NSAIDs. Au fost raportate următoarele reacţii adverse care ar putea fi în legătură cauzală cu administrarea de Movalis. Frecvenţele menţionate corespund apariţiei lor în studiile clinice, fără a se lua în considerare legătura cauzală. Datele provin din studii clinice efectuate pe 3750 de pacienţi trataţi cu doze zilnice de 7,5 mg sau 15 mg Movalis capsule sau comprimate pe o perioadă de până la 18 luni (durată medie de tratament de 127 zile). Combination use of ACE inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diuretics. The use of an ACE inhibiting drug (ACE inhibitor or angiotensin receptor antagonist), an anti-inflammatory drug (NSAID or COX-2 inhibitor) and a thiazide diuretic at the same time increases the risk of renal impairment. This includes use in fixed combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the combination. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment. Lithium. NSAIDs have been reported to increase lithium plasma levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended. If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of meloxicam treatment.

Cytochrome P450 inhibitors. Co-administration of meloxicam with drugs known to inhibit CYP 2C9 is contraindicated. Co-administration of meloxicam with drugs known to inhibit CYP 3A4 should be undertaken with caution (see Precautions, Gastrointestinal effects).you are currently taking other medicines known as: sulfinpyrazone (used to treat gout), fluconazole (used to treat fungal infections) or certain sulfur antibiotics (eg. sulfaphenazole or sulfamethoxazole).

If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous. Side effects Make sure you know how you react to it before you drive a car, operate machinery, or do anything else that could be dangerous if you are not alert.

Dosage

Studies in rats with meloxicam, as with other drugs known to inhibit prostaglandin synthesis, showed an increased incidence of still births, increased length of delivery time and delayed parturition at oral doses ≥ 1 mg/kg/day (approximately 0.6 times the human dose based on BSA), and decreased pup survival at an oral dose of 4 mg/kg/day (approximately 2.1 times the human dose based on BSA) throughout organogenesis. Similar findings were observed in rats receiving oral doses ≥ 0.125 mg/kg/day (less than 0.1 times the human dose based on BSA) during late gestation and the lactation period. Caution is advised in patients most at risk of developing a GI complication with NSAIDs: the elderly, patients using any other NSAID or aspirin concomitantly or patients with a prior history of or recent GI disease such as ulceration and GI bleeding. methotrexate, a medicine used to treat rheumatoid arthritis (a painful joint disease) and some types of cancer Other prostaglandin synthetase inhibitors (PSIs), including glucocorticoids and salicylates (acetylsalicylic acid). Coadministration of PSIs may increase the risk of gastrointestinal ulcers bleeding, via a synergistic effect, and it is not recommended. The concomitant use of meloxicam with other NSAIDs is not recommended.

Diuretics. Treatment with NSAIDs is associated with the potential for acute renal insufficiency in patients who are dehydrated. Patients receiving Movalis and diuretics should be adequately hydrated and be monitored for renal function prior to initiating treatment. Cutie cu un blister din PVC-PVDC/Al a 10 comprimate Cutie cu 2 blistere din PVC-PVDC/Al a câte 10 comprimate The extent to which metabolites of meloxicam may accumulate in patients with renal failure has not been studied. As some metabolites are excreted by the kidney, patients with significantly impaired renal function should be more closely monitored. Doza zilnică maximă recomandată adolescenţilor este de 0,25 mg/kg. Medicamentul se recomandă numai la adulţi şi adolescenţi cu vârsta peste 12 ani, deoarece nu s-a stabilit încă posologia la copii. Movalis should be used at the lowest dose and for the shortest duration consistent with effective treatment.Movalis Orodispersible Tablets should be placed in the mouth on the tongue and allowed to dissolve slowly for five minutes (the tablet should not be chewed and should not be swallowed undissolved), before swallowing with a drink of 240 ml of water. NSAIDs should be prescribed with caution in patients with a prior history of recent ulcer disease or GI bleeding. Postmarket adverse drug reactions. Additional reports of adverse events which may be causally associated to the administration of Movalis during worldwide postmarketing experience are included as follows. Caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as heparin as curative treatment or given in geriatrics, anticoagulants such as warfarin, or other non steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (> 1g as single intake or > 3g as total daily amount). daca aveti sau ati avut recent ulcer peptic sau sangerari la nivelul stomacului sau intestinului (ulceratie sau sangerare aparuta de cel putin doua ori)